A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9) | Zendy

Wendy Lane | Zendy; Elena Favaro | Zendy; Naveen Rathor | Zendy; Hak Chul Jang | Zendy; Maiken I.S. Kjærsgaard | Zendy; Alejandra Oviedo | Zendy; Ludger Rose | Zendy; Peter Senior | Zendy; Giorgio Sesti | Zendy; Alfonso González | Zendy; Edward Franek | Zendy

Open Access

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9)

Author(s) -

Wendy Lane,

Elena Favaro,

Naveen Rathor,

Hak Chul Jang,

Maiken I.S. Kjærsgaard,

Alejandra Oviedo,

Ludger Rose,

Peter Senior,

Giorgio Sesti,

Alfonso González,

Edward Franek

Publication year - 2020

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc19-2232

Subject(s) - insulin aspart , medicine , postprandial , metformin , type 2 diabetes , discontinuation , clinical endpoint , insulin degludec , hypoglycemia , insulin , randomized controlled trial , gastroenterology , diabetes mellitus , endocrinology , insulin glargine

To evaluate the efficacy and safety of fast-acting insulin aspart (faster aspart) compared with insulin aspart (IAsp), both with insulin degludec with or without metformin, in adults with type 2 diabetes not optimally controlled with a basal-bolus regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research